Stephen Oh, MD, PhD, an internationally recognized physician-scientist and hematologist, has been named the Samuel B. Grant Professor of Medicine in the Department of Medicine at Washington University School of Medicine in St. Louis.
The appointment recognizes Dr. Oh’s achievements in blood cancer research, clinical care, education, mentorship, and institutional leadership. He currently serves as Co-Chief of the Division of Hematology and Professor of Medicine at WashU Medicine.
A Career Dedicated to Blood Cancer Research
Dr. Stephen Oh’s research has significantly advanced the understanding of blood cancers, particularly myeloproliferative neoplasms, a group of disorders in which the bone marrow produces excessive numbers of blood cells.
Over the past 16 years, he has developed a highly successful translational research program focused on identifying the molecular mechanisms that contribute to the development and progression of myeloproliferative neoplasms.
His pioneering work identified dysregulated inflammatory signaling pathways as important drivers of these diseases. These findings helped establish new therapeutic strategies that were subsequently translated into clinical trials for patients.
More recently, Dr. Stephen Oh and his laboratory have identified previously unrecognized signaling dependencies in myeloproliferative neoplasms and acute myeloid leukemia. These discoveries have directly contributed to the development of innovative clinical studies and opened new possibilities for targeted treatment approaches.
From Scientific Discovery to Clinical Trials
In addition to his laboratory research, Dr. Stephen Oh is nationally recognized for his clinical expertise in myeloproliferative neoplasms.
He has served as principal investigator for more than 30 multi-site clinical trials and has contributed to several practice-changing studies that resulted in U.S. Food and Drug Administration approvals of novel treatments for patients with myeloproliferative neoplasms.
His work reflects a strong commitment to translational medicine, connecting discoveries made in the laboratory with the development and evaluation of therapies in clinical settings.
Through this combined research and clinical approach, Dr. Stephen Oh has played a major role in advancing treatment options for patients living with complex hematologic malignancies.
An Extensive Record of Scientific Scholarship
Dr. Oh has authored 100 peer-reviewed scientific publications, as well as numerous reviews, book chapters, and commentaries.
His research has appeared in leading medical and scientific journals, including Nature Medicine, Nature Genetics, Nature Cancer, Nature Communications, the New England Journal of Medicine, Blood, and the Journal of Clinical Investigation.
His research program has received continuous support from the National Institutes of Health for 15 years. His work has also been funded by organizations including the American Cancer Society, the Damon Runyon Cancer Foundation, the Doris Duke Foundation, Blood Cancer United, and the MPN Research Foundation.
Dr. Oh is frequently invited to present his research at national and international scientific conferences, reflecting his standing as a recognized leader in hematology and blood cancer research.
Recognition for Leadership in Hematology
Throughout his career, Dr. Oh has received several notable awards and honors.
These include the American Society of Clinical Oncology Young Investigator Award and the American Society of Hematology Scholar Award.
In 2025, he was elected to the American Society for Clinical Investigation in recognition of his scientific leadership and contributions to the field. Membership in the organization acknowledges physician-scientists who have made significant advances in biomedical research.
His selection as the Samuel B. Grant Professor of Medicine further recognizes the breadth of his contributions across research, patient care, education, and leadership.
Training Across Leading Academic Institutions
Dr. Oh earned his undergraduate degree in Biochemical Sciences from Harvard University.
He subsequently completed his medical degree and PhD in Cancer Biology through the Medical Scientist Training Program at Northwestern University.
Following medical school, he completed residency, fellowship, and postdoctoral training at Stanford University. He joined the faculty of Washington University School of Medicine in 2010.
Since arriving at WashU Medicine, he has developed an influential research and clinical program while assuming increasing leadership responsibilities within the Division of Hematology.
Mentoring the Next Generation of Physician-Scientists
Education and mentorship have remained central elements of Dr. Oh’s academic career.
He has mentored numerous graduate students, postdoctoral fellows, clinical fellows, and junior faculty members. His work has supported the development of researchers and clinicians preparing to build careers in hematology, oncology, and translational science.
Dr. Oh also serves as Program Director of a longstanding Molecular Hematology T32 training grant funded by the National Heart, Lung, and Blood Institute.
The program provides structured research training in molecular hematology and supports the development of future investigators in the field.
His commitment to mentorship was recognized in 2025, when he received the WashU Outstanding Faculty Award.
Strengthening Hematology at WashU Medicine
As Co-Chief of the Division of Hematology, Dr. Oh has contributed to expanding research programs, strengthening collaboration, and recruiting and developing the next generation of faculty leaders.
His leadership has supported closer connections between laboratory research, clinical investigation, patient care, and academic training.
According to the announcement, his work has strengthened both the research and clinical missions of WashU Medicine while elevating the broader field of hematology.
A Professorship Recognizing Continued Impact
The Samuel B. Grant Professorship recognizes Dr. Oh’s accomplishments as a researcher, clinician, educator, and institutional leader.
The appointment will also support his continued work in advancing scientific discovery, developing new therapeutic strategies, leading clinical research, and training future hematology specialists and physician-scientists.
Through his research into the molecular and inflammatory mechanisms of blood cancers, his leadership of clinical trials, and his commitment to mentorship, Dr. Oh has made substantial contributions to the understanding and treatment of myeloproliferative neoplasms and other hematologic malignancies.
His appointment represents recognition of those achievements and of his continued influence on hematology research and patient care.
Written by Nare Hovhannisyan, MD
Find more exclusive oncology content on OncoDaily